1197943-64-8

Basic information

• Product Name: 1-(5-bromo-2-fluorophenyl)propan-1-ol
• Synonyms: 1-(5-bromo-2-fluorophenyl)propan-1-ol
• CAS NO: 1197943-64-8
• Molecular Formula: C9H10BrFO
• Molecular Weight: 233.0775032
• Mol File: 1197943-64-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(5-bromo-2-fluorophenyl)propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-bromo-2-fluorophenyl)propan-1-ol(1197943-64-8)
• EPA Substance Registry System: 1-(5-bromo-2-fluorophenyl)propan-1-ol(1197943-64-8)

Safety Data

• Hazardous Substances Data: 1197943-64-8(Hazardous Substances Data)

Usage

General Description

1-(5-bromo-2-fluorophenyl)propan-1-ol is a chemical compound with the molecular formula C9H10BrFO. It is a white crystalline solid with a molecular weight of 227.08 g/mol. 1-(5-bromo-2-fluorophenyl)propan-1-ol is an alcohol with a propan-1-ol group and a substituted phenyl ring containing both bromine and fluorine atoms. It is used in organic synthesis and medicinal chemistry for the preparation of various pharmaceuticals and biologically active compounds. The presence of both bromine and fluorine in the phenyl ring provides unique chemical reactivity and can lead to the development of novel drug candidates with potentially interesting pharmacological properties. Additionally, it may have applications in other fields such as agrochemicals and materials science due to its unique chemical structure.

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 

Downstream Products

• 864774-67-4 5-bromo-3-ethyl-1H-indazole 

Relevant articles and documents

Maximizing lipophilic efficiency: The use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase

This paper describes the design and synthesis of a novel series of dual inhibitors of acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2). Key findings include the discovery of an initial lead that was modestly potent and subsequent medicinal chemistry optimization with a focus on lipophilic efficiency (LipE) to balance overall druglike properties. Free-Wilson methodology provided a clear breakdown of the contributions of specific structural elements to the overall LipE, a rationale for prioritization of virtual compounds for synthesis, and a highly successful prediction of the LipE of the resulting analogues. Further preclinical assays, including in vivo malonyl-CoA reduction in both rat liver (ACC1) and rat muscle (ACC2), identified an advanced analogue that progressed to regulatory toxicity studies.

FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF

The present invention relates to novel fluorinated 2,6-dialkyl-3,5-dicyano-4-(1H-indazol-5-yl)-1,4- dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the tre

2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics

A series of 2-aminothiadiazole of inhibitors of AKT1 is described. SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2). Moderate selectivity observed in several compounds for AKT1 versus PKA is rationalized by X-ray crystallographic analysis. Key compounds showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1. Compound 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40.